The central theme of my research program, Pharmaceutical Outcomes and Policy Innovations (POPi), is the study of drug therapy with the goal of improving human health and quality of life.
I am particularly interested in developing models for evaluating drug effectiveness, medication use models designed to improve patient health, and effective surveillance systems to improve the safe use of medication.
I have a particular clinical interest in pediatric medicine, with specific emphases on asthma and the epidemiology and clinical management of adverse drug reactions.
Another area of interest is the translation of knowledge to aid evidence-based drug policy development. POPi contributes to solving the international drug policy crisis on two levels: the public policy level (federal and provincial), and the clinical policy level. In this way the needs of government are served to manage drug budgets, the needs of clinicians to improve patient care, and the public need to understand and improve the effectiveness, safety and cost effectiveness of drugs.
Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research
Drögemöller BI, Brooks B, Monzon JG, Wright GE, Liu G, Renouf DJ, Kollmannsberger C, Bedard PL, Hayden MR, Gelmon KA, Carleton B, Ross CJ
An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Pediatric blood & cancer
Dionne F, Aminkeng F, Bhavsar AP, Groeneweg G, Smith A, Visscher H, Rassekh SR, Ross C, Carleton B
Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study.
Smy L, Shaw K, Amstutz U, Staub M, Chaudhry S, Smith A, Carleton B, Koren G
Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Carleton BC
Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity.
Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC, CPNDS Clinical Practice Recommendations Group
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ, Canadian Pharmacogenomics Network for Drug Safety Consortium
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, CPNDS clinical recommendation group
The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.
Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR, CPNDS Consortium
Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database.
Liu RT, Yeung SN, Carleton B, Etminan M
Association of Post-operative Topical Prostaglandin Analog or Beta-blocker Use and Incidence of Pseudophakic Cystoid Macular Edema.
Journal of glaucoma
Wendel C, Zakrzewski H, Carleton B, Etminan M, Mikelberg FS
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Clinical pharmacology and therapeutics
Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL, Mushiroda T, Pirmohamed M
Risk of hair loss with different antidepressants: a comparative retrospective cohort study.
International clinical psychopharmacology
Etminan M, Sodhi M, Procyshyn RM, Guo M, Carleton BC
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.
McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Cavalleri GL
SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.
The journal of allergy and clinical immunology. In practice
White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Phillips EJ
Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.
PM & R : the journal of injury, function, and rehabilitation
McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS
Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
Sodhi M, Sheldon CA, Carleton B, Etminan M
Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Cheng JZ, Sodhi M, Etminan M, Carleton BC
Physician and parent barriers to the use of oral corticosteroids for the prevention of paediatric URTI-induced acute asthma exacerbations at home.
Paediatrics & child health
Smith N, Smith A, Wang A, Shaw K, Groeneweg G, Goldman RD, Wilkinson B, Jimenez R, Mwai L, Carleton B
Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.
Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Maitland-van der Zee AH
Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy.
Journal of the neurological sciences
Horvath GA, Meisner L, Selby K, Stowe R, Carleton B
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton B, Tremlett H
Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
British journal of clinical pharmacology
Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC
Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.
Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
Canadian journal of kidney health and disease
McMahon KR, Rod Rassekh S, Schultz KR, Pinsk M, Blydt-Hansen T, Mammen C, Tsuyuki RT, Devarajan P, Cuvelier GD, Mitchell LG, Baruchel S, Palijan A, Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC
Oral morphine dosing predictions based on single dose in healthy children undergoing surgery.
Dawes JM, Cooke EM, Hannam JA, Brand KA, Winton P, Jimenez-Mendez R, Aleksa K, Lauder GR, Carleton BC, Koren G, Rieder MJ, Anderson BJ, Montgomery CJ
Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study.
Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC
Asthma in British Columbia: Are We Finally Breathing Easier? A population based study of the burden of disease Over 14 Years.
Bardal S, Smith A, Luo HA, Zhang T, Groeneweg G, Jimenez Mendez R, Goldman R, Carleton B
An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration.
Torosyan Y, Hu Y, Hoffman S, Luo Q, Carleton B, Marinac-Dabic D
Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M, Maberley DA, Babiuk DW, Carleton BC
Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.
Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH
Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW, Pussegoda K, Rassekh RS, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC, CPNDS clinical recommendations group
Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.
Etminan M, Maberley DA, Babiuk DW, Carleton BC
Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.
Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton B, Hayden MR, Teo YY, Dissanayake VH, Brunham LR
Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study.
Smy L, Shaw K, Amstutz U, Smith A, Berger H, Carleton B, Koren G
A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N, Jimenez-Mendez R, Cooke E, Montgomery CJ, Dawes J, Rieder MJ, Aleksa K, Koren G, Jacobo-Cabral CO, Gonzalez-Ramirez R, Castañeda-Hernandez G, Carleton BC
Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, Jiménez-Méndez R, Medina A, Clark P, Rassekh R, Castañeda-Hernández G, Carleton B, Medeiros M, Canadian Pharmacogenomics Network for Drug Safety Consortium
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC, CPNDS Clinical Recommendation Group
Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children.
Smy L, Shaw K, Smith A, Russell E, Van Uum S, Rieder M, Carleton B, Koren G
New Ways of Detecting ADRs in Neonates and Children.
Jimenez R, Smith A, Carleton B
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ, CPNDS consortium
Pharmacogenomic diversity in Singaporean populations and Europeans.
Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, Hayden MR, Sung C, Teo YY
Emergency department visits for children with acute asthma: discharge instructions, parental plans, and follow-through of care--a prospective study.
Camp PG, Norton SP, Goldman RD, Shajari S, Smith MA, Heathcote S, Carleton B
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H
Genetic markers of cisplatin-induced hearing loss in children.
Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR
Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A, Clark P, Carleton B, Ross C, Hildebrand C, Castañeda-Hernández G, Rivas-Ruiz R
Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR
The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC
Codeine-related deaths: The role of pharmacogenetics and drug interactions.
Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P
Development of a broad-based ADME panel for use in pharmacogenomic studies.
Brown AM, Renaud Y, Ross C, Hansen M, Mongrain I, Valois D, Carleton BC, Hayden MR, Dubé MP, Tardif JC, Phillips MS
Rising antipsychotic prescriptions for children and youth: cross-sectoral solutions for a multimodal problem.
Di Pietro N, Illes J, Canadian Working Group on Antipsychotic Medications and Children
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.
Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR
Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions.
Amstutz U, Shyr C, Shear NH, Rieder MJ, Wasserman WW, Ross CJ, Carleton BC
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, CPNDS Consortium
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR, CPNDS Consortium
Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.
Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC, CPNDS Consortium
The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.
Kowalec K, Carleton B, Tremlett H
High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada.
Zhang T, Smith MA, Camp PG, Carleton BC
Prescription drug dispensing profiles for one million children: a population-based analysis.
Zhang T, Smith MA, Camp PG, Shajari S, MacLeod SM, Carleton BC
Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient.
Kowalec K, Yoshida EM, Traboulsee A, Carleton B, Tremlett H
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, CPNDS Clinical Recommendations Group
A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.
Kelly LE, Chaudhry SA, Rieder MJ, 't Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Koren G
Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment.
Siden HB, Carleton BC, Oberlander TF
Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT.
Shaw K, Amstutz U, Castro-Pastrana L, Loo TT, Ross CJ, Ito S, Reider MJ, Maher M, Macleod S, Koren G, Hayden MR, Carleton BC
Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?
Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G
The use of long-acting ß2- agonists as monotherapy in children and adults.
Camp PG, Zhang T, Smith MA, Carleton BC
Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study.
Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G
Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details.
Lam J, Matlow JN, Ross CJ, Hayden MR, Carleton BC, Madadi P
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR
More codeine fatalities after tonsillectomy in North American children.
Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium
Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.
Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML, Nauta M, Carleton BC, Koren G, Hayden MR
Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia.
Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, Koren G
Using pharmacogenetics to understand adverse drug reactions in children.
Shaw K, Amstutz U, Carleton BC
Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.
Joly Y, Koutrikas G, Ramos-Paque E, Zawati M, Gardy J, Hayden MR, Carleton BC
CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G
A literature review on distance knowledge exchange in healthcare groups: what can we learn from the ICT literature?
Househ MS, Kushniruk A, Carleton B, Cloutier-Fisher D
Phenotype standardization for immune-mediated drug-induced skin injury.
Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH
The use of conferencing technologies to support drug policy group knowledge exchange processes: an action case approach.
Househ MS, Kushniruk A, Maclure M, Carleton B, Cloutier-Fisher D
Sildenafil citrate therapy for severe early-onset intrauterine growth restriction.
von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group
A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ
Pharmacogenomics of serious adverse drug reactions in pediatric oncology.
Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR
Strengths and weaknesses of using conferencing technologies to support drug policy knowledge exchange.
Househ MS, Kushniruk AW, Macclure M, Carleton B, Cloutier-Fisher D
Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.
Castro-Pastrana LI, Carleton BC
The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study.
Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, D Ross CJ, Carleton BC, Hayden MR, Koren G
Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS).
Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B
Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y, Koutrikas G, Tassé AM, Issa A, Carleton B, Hayden M, Rieder MJ, Ramos-Paque E, Avard D
Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits.
Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, Ross CJ, Carleton BC, Hayden MR, Koren G
Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G
Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC
Palivizumab for the prevention of respiratory syncytial virus infection.
Rogovik AL, Carleton B, Solimano A, Goldman RD
The comorbidity burden of the treated asthma patient population in British Columbia.
Prosser R, Carleton B, Smith A
Direct health care costs associated with asthma in British Columbia.
Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, Fitzgerald JM
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR, CPNDS Consortium
Application of principal component analysis to pharmacogenomic studies in Canada.
Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR
Use of oseltamivir in children.
Jamieson B, Jain R, Carleton B, Goldman RD
Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals.
Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G
Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
Wong E, Carleton BC, Wright DF, Smith MA, Verbeek L, Hildebrand CA, Stannard P, Vaillancourt R, Elliot-Miller P, Ross CJ, Hayden MR
A case study examining the impacts of conferencing technologies in distributed healthcare groups.
Househ M, Kushniruk A, Maclure M, Carleton B, Cloutier-Fisher D
Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are.
Maclure M, Warren L, Willison D, Cassels A, Carleton B
Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces.
Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A
Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
Maclure M, Carleton B, Schneeweiss S
Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.
Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR
Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study.
Norton SP, Pusic MV, Taha F, Heathcote S, Carleton BC
Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC, Smith MA, Gelin MN, Heathcote SC
Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.
Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, Côté AM, von Dadelszen P
Formulas containing live probiotic bacteria.
Falk J, Carleton B, Gerber P
Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials.
Etminan M, Carleton B, Delaney JA, Padwal R
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.
Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J
Recognizing idiosyncratic adverse drug reactions in children: A practice imperative.
Carleton B, Primmett D
From professional advocacy to patient advocacy: a gambit for pharmacists.
Simple approach to dosage adjustment in patients with renal impairment.
McCormack JP, Cooper J, Carleton B
A simpler approach to pharmacokinetic dosage adjustments.
McCormack JP, Carleton B
Drug and poison information resources on the Internet, Part 2: Identification and evaluation.
Marra CA, Carleton BC, Lynd LD, Marra F, McDougal AR, Chow D, McKerrow R
Overview of health-related quality-of-life measures for pediatric patients: application in the assessment of pharmacotherapeutic and pharmacoeconomic outcomes.
Marra CA, Levine M, McKerrow R, Carleton BC
Drug and poison information resources on the Internet, Part 1: An introduction.
Marra CA, Lynd LD, McKerrow R, Carleton BC
Comment: cost of rhDNase in cystic fibrosis.
Marra CA, Carleton BC, Basmadjian D, Levine M, McKerrow R
Spurious rise in total carbon dioxide and chloride with negative anion gap after cystogram.
Abdel-Wareth LO, Lirenman DS, Halstead AC, McLellan D, Carleton BC
Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy.
Canafax DM, Carleton BC, Matas AJ, Payne WD, Dunn DL, Sutherland DE, Najarian JS
Method for evaluating drip-rate accuracy of intravenous flow-regulating devices.
Carleton BC, Cipolle RJ, Larson SD, Canafax DM
Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans.
Erdmann GR, Steury JC, Carleton BC, Stafford RJ, Bostrom BC, Canafax DM
Interaction between cyclosporine and fluconazole in renal allograft recipients.
Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ
Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study.
Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ
Genomic and Outcomes Databank for Pharmacogenomic and Implementation Studies (GO PGx)
This Genome Canada project will reduce adverse drug reactions (ADRs) by developing genomic-based precision health strategies and technologies for the most common and severe ADRs in pediatric oncology and facilitate the implementation of pharmacogenomics into clinical practice. This will be realized through four parallel and complementary research activities that will result in genomic-based precision health deliverables for unique end-users:
1. Establish an ADR database of linked clinical and genomic data to discover and validate biomarkers of five severe ADRs associated with cancer therapy drugs in children.
2. Knowledge translation (KT) to facilitate the use of pharmacogenomics in pediatric oncology through the development of clinical practice guidelines and an educational program.
3. Implement ADR-predictive pharmacogenomics tests at 10 pediatric oncology centres across Canada
4. Exploration of how pharmacogenomics testing in pediatric oncology impacts, and is impacted by patients, families, clinicians, and the Canadian healthcare system (GE3LS).
Integrating pediatric pharmacogenomic testing into the Canadian health care system
This project is focused on developing pharmacogenomic tests to predict the risk of experiencing an adverse drug reaction (ADR) in pediatric patients, and strives to bridge the gap between the rigorous science of pharmacogenomics and its integration into health care by providing a tool for the clinical uptake of rigorously derived pharmacogenomic information. To bridge this gap, we have identified actionable pharmacogenomic biomarkers for the most frequently prescribed medication classes and associated ADRs in children: antibiotics, analgesics, and mental health medications. These pharmacogenomic biomarkers all have a compelling rationale for inclusion and were based upon recommendations from FDA and/or Health Canada, Clinical Practice Guidelines, or discovery and replication of research findings in at least three independent populations. Using these robust genomic findings, we will develop three pharmacogenomic panels that possess high analytical validity as well as clinical utility. This product will therefore make the proven benefits of pharmacogenomics accessible to all pediatric patients and their clinicians and pharmacists in Canada. The availability of such tests would provide huge advantages to the thousands of children receiving these frequently prescribed medications every year and will significantly decrease the prevalence of severe and debilitating ADRs related to the most commonly prescribed medications in children.Grants
DSEN-SEARCH: active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare – CIHR (2011-2014)
The Canadian Pharmacogenomics Network for Drug Safety - Canada Foundation for Innovation/ Canadian Institutes for Health Research (2008-2013)
DSEN-PREVENT: Pharmacogenomics of Adverse Reactions EVEnts Nation-wide Team – CIHR (2011-2014)
Pharmacogenomics of Warfarin Safety and Effectiveness in Children – CIHR (2012-2013)Honours & Awards
2011 Canadian Society of Pharmacology and Therapeutics (CSPT) Senior Investigator Award
2009 Award for Clinical Research, CIHR Institute of Human Development, Child and Youth Health (IHDCYH) for the Best Research Poster: Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic obstructive pulmonary disease and the impact of coexisting asthma. Presented at the IHDCYH Scientific Forum, Winnipeg Manitoba, May 2009.
2008 Awards for Clinical Research, Canadian Association of Paediatric Health Centres (CAPHC) and McMaster University Child Health Research Institute for the Best Research Poster: Genotypic Approaches to Therapy in Children: A National ADR Surveillance Network to Study and Prevent Severe Adverse Drug Reactions in Children. Presented at the CAPHC Annual meeting, Edmonton Alberta, October 2008.Research Group Members
Gabriella Groeneweg, Program Manager
Jessica Trueman, Research Assistant
Erandika Prasadani Gunaretnam, Research Technician
Kathy Wan-Chun Chang
Victor Wong, Undergraduate Student
Angeleet Dhanda, Undergraduate Student
Tan Toan Le
Ellen Kim, Research Staff